Well, right now it’s a limited role because even though both drugs are approved, we wouldn’t suggest using them based on this work, but we would suggest studying other inhibitors, you know, so potentially trying to figure out a way to say, for example, reduce the toxicity that was driven by the CDK4-6 inhibitor. There are other CDK4-6 inhibitors that are FDA approved, and as I mentioned, some pathway inhibitors are also in clinical development...
Well, right now it’s a limited role because even though both drugs are approved, we wouldn’t suggest using them based on this work, but we would suggest studying other inhibitors, you know, so potentially trying to figure out a way to say, for example, reduce the toxicity that was driven by the CDK4-6 inhibitor. There are other CDK4-6 inhibitors that are FDA approved, and as I mentioned, some pathway inhibitors are also in clinical development. If they were less toxic, that might be an approach that might make more sense because then the cost benefit would be more in favor of the increased toxicity. So I think there’s a future there, but it’s going to depend on future studies to get us there.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
